Table 1.
Prospective studies involving the use of single-fraction SBRT in the definitive treatment of extracranial malignancies
| Authors (year) | Study type | Primary diagnosis | No patients | Dose (Gy) | Median follow-up (months) | Local control | Acute/late grade ≥3 toxicity |
|---|---|---|---|---|---|---|---|
| Videtic et al (2015, 2019)18,19 | Phase II | NSCLC | 94 | 34 | 30.2 | 1 y 97% 5 y 89.4% |
2.6% |
| Singh et al (2019)20 | Phase II | NSCLC | 98 | 30 | 53.8 | 2 y 94.9% | 16% |
| Koong et al (2004)35 | Phase I | Pancreas | 15 | 15-25 | NR | 1 y 100% | 0% acute |
| Schellenberg et al (2008)36 | Phase I/II | Pancreas | 16 | 25 | 9.1 | 1 y 100% | 6% acute 13% late |
| Schellenberg et al (2011)38 | Phase I/II | Pancreas | 20 | 25 | 11.8 | 1 y 94% | 0% acute 5% late |
| Staehler et al (2015)50 | Phase I/II | RCC | 30 | 25 | 28.1 | 9 mo 98% | 0% acute 0% late |
| Siva et al (2017)52 | Phase I/II | RCC | 17 | 26 | 24 | 2 y 100% | 0% acute 3% late |
| Greco et al (2018)60,∗ | Phase II | Prostate | 15 | 24 | NR | NR | 0% acute |
Abbreviations: NR = not reported; NSCLC = non-small cell lung cancer; RCC = renal cell carcinoma; SBRT = stereotactic body radiation therapy.
∗
Abstract only.